|Having trouble viewing this email? Click here|
Physicians: .25 AMA PRA Category I CreditsTM
To Receive Credit
In order to receive your certificate of participation, you should read the information about this activity, including the disclosure statements, review the entire activity, take the post-test, and complete the evaluation form. You may then follow the directions to print your certificate of participation. To begin, click the CME icon above.
Upon successful completion of this educational program, the reader should be able to:
Alan Ehrlich, MD
Dr. Ehrlich, Dr. Fleming, DynaMed Editorial Team members, and the staff of Antidote Education Company have disclosed that they have no relevant financial relationships or conflicts of interest with commercial interests related directly or indirectly to this educational activity.
ACCME: This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Antidote Education Company and EBSCO Publishing. Antidote is accredited by the ACCME to provide continuing medical education for physicians. Antidote Education Company designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Looking for a change? The DynaMed editorial team is expanding and looking for talented and driven individuals. Visit the links below to learn about these exciting opportunities.
DynaMed Contribution Opportunities
Call for Peer Reviews
We are currently seeking subspecialty reviewers for our Patient Education Resource Center (PERC). PERC provides fact sheets and discharge instructions for patients leaving the hospital or emergency room. These hand-outs fulfill the meaningful use requirements for the Medicare & Medicare Services Incentive Programs.
Last week 505 journal articles were evaluated via DynaMed's Systematic Literature Surveillance and summaries of 225 articles were added to DynaMed content.
Dalbavancin and Oritavancin Each Have Similar Efficacy to Vancomycin in Patients with Serious Bacterial Skin and Skin Structure Infections
Skin and skin-structure infections are common and represent a significant burden for hospitals and primary care practices. A recent population-based study in the United States estimated that there were 496 clinically diagnosed skin or soft tissue infections per 10,000 person-years, which translates to more than 15 million new cases annually in the U.S. (BMC Infect Dis 2013 May 30;13(1):252 full-text). Staphylococcus aureus is an important causative agent of these infections, and methicillin-resistant S. aureus, or MRSA, can be particularly difficult to treat. When MRSA is suspected among hospitalized patients with complicated skin and skin tissue infections, such as purulent cellulitis, the glycopeptide antibiotic vancomycin is a treatment option (Clin Infect Dis 2011 Feb;52(3):e18 full-text). Lipoglycopeptide analogs such as dalbavancin (an analog of teicoplanin) and oritavancin (an analog of vancomycin) share a similar mechanism to their glycopeptide counterparts, but have important differences in pharmacologic properties. Two recent studies, one evaluating dalbavancin and the other evaluating oritavancin, assessed whether these analogs were noninferior to vancomycin in patients with acute bacterial skin and skin-structure infections.
EBSCO Health Launches Pediatric Clinical Information Mobile App
PEMSoft Now Available For iPhone, iPad, and Android Devices
A mobile app designed specifically for pediatricians, emergency department physicians, physicians-in-training and other medical providers caring for children with acute illnesses and injury, is now available from EBSCO Health, the leading provider of clinical decision support solutions for the healthcare industry.
DynaMed EventsMedical Marijuana: Regs, Responsibilities & Communication
June 18, 2014 / 8am-12:30pm
Senior Deputy Editor Alan Ehrlich, MD, will be presenting Medical Marijuana: An Evidenced-Based Assessment of Efficacy and Harms at the Massachusetts Medical Society (MMS) CME Event and Conference.